DEXCOM INC

NASDAQ: DXCM (DexCom, Inc.)

Last update: 28 Nov, 12:05PM

63.47

0.94 (1.50%)

Previous Close 62.53
Open 62.57
Volume 2,241,246
Avg. Volume (3M) 6,460,861
Market Cap 24,890,095,616
Price / Earnings (TTM) 35.26
Price / Earnings (Forward) 25.84
Price / Sales 5.85
Price / Book 9.28
52 Weeks Range
54.11 (-14%) — 93.25 (46%)
Earnings Date 30 Oct 2025
Profit Margin 12.90%
Operating Margin (TTM) 12.91%
Diluted EPS (TTM) 1.33
Quarterly Revenue Growth (YOY) 12.50%
Quarterly Earnings Growth (YOY) -28.00%
Total Debt/Equity (MRQ) 113.97%
Current Ratio (MRQ) 1.50
Operating Cash Flow (TTM) 964.10 M
Levered Free Cash Flow (TTM) 509.04 M
Return on Assets (TTM) 5.97%
Return on Equity (TTM) 23.72%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock DexCom, Inc. Bearish Bearish

AIStockmoo Score

1.6
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 1.5
Technical Moving Averages 1.0
Technical Oscillators 2.0
Average 1.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DXCM 25 B - 35.26 9.28
PODD 22 B - 97.43 15.63
SSII 1 B - - 30.33
IRTC 6 B - - 48.07
TMDX 4 B - 51.55 14.05
ESTA 2 B - - 125.60

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Sector Healthcare
Industry Medical Devices
Investment Style Mid Growth
% Held by Insiders 0.42%
% Held by Institutions 97.10%
52 Weeks Range
54.11 (-14%) — 93.25 (46%)
Price Target Range
68.00 (7%) — 99.00 (55%)
High 99.00 (Canaccord Genuity, 55.98%) Buy
Median 85.00 (33.92%)
Low 68.00 (Evercore ISI Group, 7.14%) Hold
Average 83.82 (32.06%)
Total 14 Buy, 3 Hold
Avg. Price @ Call 60.65
Firm Date Target Price Call Price @ Call
Morgan Stanley 02 Dec 2025 75.00 (18.17%) Buy 64.45
10 Nov 2025 63.00 (-0.74%) Hold 54.84
Evercore ISI Group 25 Nov 2025 68.00 (7.14%) Hold 61.69
Argus Research 07 Nov 2025 90.00 (41.80%) Buy 55.00
Barclays 03 Nov 2025 80.00 (26.04%) Hold 60.43
Truist Securities 03 Nov 2025 82.00 (29.19%) Buy 60.43
15 Oct 2025 94.00 (48.10%) Buy 65.41
UBS 03 Nov 2025 95.00 (49.68%) Buy 60.43
BTIG 31 Oct 2025 85.00 (33.92%) Buy 58.22
Canaccord Genuity 31 Oct 2025 99.00 (55.98%) Buy 58.22
29 Sep 2025 106.00 (67.01%) Buy 66.46
Citigroup 31 Oct 2025 75.00 (18.17%) Buy 58.22
07 Oct 2025 85.00 (33.92%) Buy 66.03
JP Morgan 31 Oct 2025 75.00 (18.17%) Hold 58.22
Piper Sandler 31 Oct 2025 75.00 (18.17%) Buy 58.22
RBC Capital 31 Oct 2025 85.00 (33.92%) Buy 58.22
TD Cowen 31 Oct 2025 84.00 (32.35%) Buy 58.22
Wells Fargo 31 Oct 2025 93.00 (46.53%) Buy 58.22
Stifel 21 Oct 2025 85.00 (33.92%) Buy 69.75
Goldman Sachs 01 Oct 2025 89.00 (40.22%) Buy 66.08
Baird 26 Sep 2025 90.00 (41.80%) Buy 67.10
Show more

No data within this time range.

Date Type Details
05 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
05 Dec 2025 Announcement SueWallSt Podcast Series Launches With Focus on DexCom, Inc. (DXCM) Fraud Allegations
04 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
04 Dec 2025 Announcement Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
04 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Dec 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
02 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
02 Dec 2025 Announcement Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
01 Dec 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
01 Dec 2025 Announcement Tune Into the SueWallSt Podcast: DexCom, Inc. (DXCM) Lawsuit Explained
25 Nov 2025 Announcement GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
25 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
20 Nov 2025 Announcement Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
20 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
19 Nov 2025 Announcement Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
18 Nov 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
18 Nov 2025 Announcement DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
17 Nov 2025 Announcement Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations
14 Nov 2025 Announcement Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
06 Nov 2025 Announcement Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
06 Nov 2025 Announcement Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now
30 Oct 2025 Announcement Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
27 Oct 2025 Announcement Dexcom Appoints Euan Ashley to Board of Directors
02 Oct 2025 Announcement Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
15 Sep 2025 Announcement Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
10 Sep 2025 Announcement Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria